Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesSonoma Pharmaceuticals Inc

Sonoma Pharmaceuticals Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
1.215 USD -0.03 ( 2.02%)
Last update at 2026-11-12T15:48:00Z
VOLUME
38288
Market Cap
6.13M

Momentum Score

…

Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.20
Low
1.27
High
52 Week Price Range
0.85
Low
4.60
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
1.24
Dividend Yield
-
Revenue TTM
21.92M
Revenue Per Share
9.81
Gross Profit TTM
8.53M
Debt / Equity
0.27
ROE
-42.52%
Net Debt
-1.56M
ROCE
-26.96%
Diluted EPS TTM
-1.22

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Income before tax -3.42M -2.91M -5.03M -5.18M -5.42M
Net income -3.17M -3.46M -4.83M -5.15M -5.09M
Selling general administrative 7.61M 7.17M 7.42M 8.84M 9.76M
Selling and marketing expenses - 0.19M 0.16M - -
Gross profit 7.42M 5.46M 4.75M 4.48M 3.99M
Reconciled depreciation 0.14M 0.14M 0.18M 0.12M 0.19M
Ebit -2.46M -2.91M -5.03M -4.57M -5.89M
Ebitda -2.32M -2.77M -4.86M -4.45M -6.57M
Depreciation and amortization 0.14M 0.14M 0.18M 0.12M -0.69M
Operating income -2.46M -3.71M -4.70M -4.57M -5.89M
Other operating expenses 21.99M 18.00M 17.44M 17.84M 18.52M
Interest expense - - - 0.02M -0.01M
Tax provision -0.24M 0.55M -0.20M -0.03M -0.33M
Net interest income - - - 0.02M -0.01M
Income tax expense -0.24M 0.55M -0.20M -0.03M -0.33M
Total revenue 19.53M 14.29M 12.73M 13.27M 12.63M
Total operating expenses 9.88M 9.18M 9.45M 9.05M 9.88M
Cost of revenue 12.11M 8.82M 7.99M 8.79M 8.63M
Total other income expense net -0.96M 0.80M -0.33M -0.61M 0.47M
Net income from continuing ops -3.17M -3.46M -4.83M -5.15M -5.09M
Net income applicable to common shares - - - -5.15M -5.09M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total assets 13.96M 13.69M 14.74M 16.23M 18.84M
Other current assets 0.61M 0.60M 0.71M 4.55M 1.59M
Total liab 10.87M 9.28M 8.60M 8.25M 10.15M
Total stockholder equity 3.10M 4.41M 6.14M 7.98M 8.70M
Other current liab -3.31M 2.22M -2.60M 2.03M 1.84M
Common stock - - 0.00M 0.01M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.01M 0.00M
Retained earnings -200.98M -197.81M -194.35M -189.51M -184.36M
Other liab - - - 4.38M 4.02M
Other assets - - - 1.53M 1.54M
Cash 2.40M 5.37M 3.13M 3.82M 7.40M
Total current liabilities 4.83M 4.10M 3.72M 3.72M 5.82M
Current deferred revenue 0.28M 0.64M 0.48M 0.16M 1.28M
Net debt -1.56M -5.07M -2.52M -2.97M -6.03M
Short term debt 0.37M 0.28M 0.52M 0.69M 1.06M
Short long term debt 0.22M 0.22M 0.32M 0.43M 0.81M
Short long term debt total 0.84M 0.30M 0.61M 0.85M 1.37M
Other stockholder equity 207.32M 206.59M 203.21M 200.90M 197.37M
Property plant equipment - - - 0.91M 0.88M
Total current assets 12.10M 12.65M 12.55M 13.80M 16.43M
Net tangible assets - - - 7.98M 8.70M
Net receivables 5.43M 3.76M 5.99M 6.42M 4.78M
Inventory 3.65M 2.92M 2.72M 2.86M 2.66M
Accounts payable 1.92M 0.95M 0.61M 0.84M 1.64M
Accumulated other comprehensive income -3.24M -4.38M -2.72M -3.42M -4.31M
Non currrent assets other 0.06M 0.15M 0.40M 0.58M 0.71M
Non current assets total 1.86M 1.04M 2.19M 2.43M 2.42M
Capital lease obligations 0.62M 0.09M 0.28M 0.42M 0.56M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Investments - -0.08M -0.00M -0.26M -0.10M
Change to liabilities - - - -2.16M 0.74M
Total cashflows from investing activities -0.19M -0.08M -0.00M -0.26M -0.10M
Net borrowings -0.27M -0.40M -0.48M -0.38M -0.37M
Total cash from financing activities 0.48M 3.03M 1.68M 2.49M 7.40M
Change to operating activities - - - -0.16M 0.16M
Net income -3.17M -3.46M -4.83M -5.15M -5.09M
Change in cash -2.98M 2.25M -0.69M -3.58M 3.18M
Begin period cash flow 5.37M 3.13M 3.82M 7.40M 4.22M
End period cash flow 2.40M 5.37M 3.13M 3.82M 7.40M
Total cash from operating activities -3.93M -0.09M -2.40M -6.15M -4.25M
Issuance of capital stock 0.43M 3.08M 1.78M 2.87M 7.55M
Depreciation 0.14M 0.14M 0.18M 0.12M 0.19M
Other cashflows from investing activities - - 0.01M 0.01M 0.04M
Change to inventory -0.47M -0.39M 0.18M 0.04M -0.10M
Change to account receivables -0.12M 0.43M -0.23M 0.06M 1.97M
Sale purchase of stock 0.00M -0.00M 0.00M - -
Other cashflows from financing activities 0.28M 0.36M 0.37M 2.61M 0.34M
Change to netincome - - - 0.74M -2.48M
Capital expenditures 0.19M 0.08M 0.02M 0.27M 0.14M
Change in working capital -0.41M 2.48M 1.69M -1.86M 3.13M
Stock based compensation 0.26M 0.22M 0.52M 0.67M 0.38M
Other non cash items -0.52M 0.17M 0.16M 0.11M -2.03M
Free cash flow -4.12M -0.17M -2.42M -6.42M -4.38M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SNOA
Sonoma Pharmaceuticals Inc		 -0.03
2.02%		 1.22 - 46.08 0.28 0.92 0.07 11.46
MKKGY
Merck KGaA ADR		 -0.74
2.19%		 33.06 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -
-%		 170.05 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 0.34
1.66%		 21.18 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.72 - 10.66 0.01 1.16 2.94 23.11

Profile*

Sonoma Pharmaceuticals Inc

Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

5445 Conestoga Court, Boulder, CO, United States, 80301

800 759 9305

https://sonomapharma.com

10

Name Title Year Born
Ms. Amy M. Trombly CEO, Pres & Director 1968
Mr. Bruce Thornton COO & Corp. Sec. 1964
Mr. Jerome Dvonch Exec. Officer 1968
Mr. Chad White Interim Chief Financial Officer 1973
Dr. Robert Northey Exec. VP of R&D 1957
Ms. Victoria Covel Assistant Controller NA
Ms. Amy M. Trombly CEO, President & Director 1968
Mr. Jerome J. Dvonch Interim Chief Financial Officer 1968
Mr. Bruce Thornton COO & Corporate Secretary 1964
Mr. John Dal Poggetto Controller 1972

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…